U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ovarian Carcinoma

MedGen UID:
1651209
•Concept ID:
C4725612
•
Neoplastic Process

Definition

Ovarian carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr
J Clin Oncol 1990 Jan;8(1):146-50. doi: 10.1200/JCO.1990.8.1.146. PMID: 2295905
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Markman M
Semin Oncol 1989 Aug;16(4 Suppl 6):79-82. PMID: 2669140

Recent clinical studies

Etiology

Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W, Li Z, Zheng Z, Wu X
Cancer Med 2020 Aug;9(16):5899-5907. Epub 2020 Jul 6 doi: 10.1002/cam4.3282. PMID: 32627959Free PMC Article
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F
Cancer 1996 Oct 1;78(7):1452-60. doi: 10.1002/(SICI)1097-0142(19961001)78:7<1452::AID-CNCR12>3.0.CO;2-Z. PMID: 8839551
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143. PMID: 7774830
Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age.
Cornelison TL, Reed E
Cancer 1993 Jan 15;71(2 Suppl):650-5. doi: 10.1002/cncr.2820710225. PMID: 8420690

Diagnosis

Inflammatory skin metastases from ovarian carcinoma--a case report and review of the literature.
Schonmann R, Altaras M, Biron T, Bernheim J, Fishman A
Gynecol Oncol 2003 Sep;90(3):670-2. doi: 10.1016/s0090-8258(03)00366-4. PMID: 13678744
Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K, Kikuchi Y, Kudoh K, Nagata I
J Cancer Res Clin Oncol 2000 Mar;126(3):168-72. doi: 10.1007/s004320050027. PMID: 10741911
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.
Long HJ
Mayo Clin Proc 1994 Apr;69(4):341-5. doi: 10.1016/s0025-6196(12)62219-8. PMID: 7909575
Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.
Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis RL, O'Dwyer PJ
Gynecol Oncol 1991 Dec;43(3):242-6. doi: 10.1016/0090-8258(91)90028-4. PMID: 1752494

Therapy

The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
Kanis M, Kesterson JP, Lele S
Eur J Gynaecol Oncol 2009;30(4):387-8. PMID: 19761128Free PMC Article
Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.
Long HJ
Mayo Clin Proc 1994 Apr;69(4):341-5. doi: 10.1016/s0025-6196(12)62219-8. PMID: 7909575
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Markman M
Semin Oncol 1989 Aug;16(4 Suppl 6):79-82. PMID: 2669140
A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W, Lewis JL Jr
J Clin Oncol 1988 Apr;6(4):689-95. doi: 10.1200/JCO.1988.6.4.689. PMID: 3128649

Prognosis

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143. PMID: 7774830
Salvage therapy in epithelial ovarian cancer.
Caldas C, Morris LE, McGuire WP 3rd
Obstet Gynecol Clin North Am 1994 Mar;21(1):179-94. PMID: 8015763
Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.
Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR Jr, Weadock K, Tumeh SS, Lavin P
Gynecol Oncol 1992 Jun;45(3):265-72. doi: 10.1016/0090-8258(92)90302-y. PMID: 1612502
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH
J Clin Oncol 1992 Apr;10(4):647-56. doi: 10.1200/JCO.1992.10.4.647. PMID: 1312588

Clinical prediction guides

Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
Galligioni E, Arcuri C, Sorio R, Griso C
Ann Oncol 2006 May;17 Suppl 5:v195-8. doi: 10.1093/annonc/mdj980. PMID: 16807455
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
Long HJ 3rd, Nelimark RA, Su JQ, Garneau SC, Levitt R, Goldberg RM, Poon MA, Kugler JW
Gynecol Oncol 1994 Aug;54(2):180-3. doi: 10.1006/gyno.1994.1190. PMID: 8063243
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article
A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W, Lewis JL Jr
J Clin Oncol 1988 Apr;6(4):689-95. doi: 10.1200/JCO.1988.6.4.689. PMID: 3128649

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...